Australia markets closed

Stevanato Group S.p.A. (STVN)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
32.10+0.23 (+0.72%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close31.87
Open31.31
Bid30.40 x 900
Ask36.27 x 1200
Day's range30.77 - 32.14
52-week range23.00 - 36.30
Volume298,584
Avg. volume336,736
Market cap8.725B
Beta (5Y monthly)0.72
PE ratio (TTM)53.50
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.06 (0.19%)
Ex-dividend date07 June 2023
1y target estN/A
  • Business Wire

    Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters’ Option to Purchase Additional Ordinary Shares

    PIOMBINO DESE, Italy, March 26, 2024--Stevanato Group S.p.A. (NYSE: STVN) ("Stevanato Group," or the "Company"), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the closing of its previously announced upsized underwritten public offering of an aggregate of 14,605,000 of its ordinary shares, which includes the full exercise of the underwriters’ option to purchase 1,905,000 addi

  • Business Wire

    Stevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares

    PIOMBINO DESE, Italy, March 22, 2024--Stevanato Group S.p.A. (NYSE: STVN) ("Stevanato Group," or the "Company"), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share.

  • Business Wire

    Stevanato Group Announces Public Offering of Ordinary Shares

    PIOMBINO DESE, Italy, March 20, 2024--Stevanato Group S.p.A. (NYSE: STVN) ("Stevanato Group," or the "Company"), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the launch of an underwritten public offering of an aggregate of $300,000,000 of its ordinary shares.